These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 16772751

  • 1. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
    Nordberg A.
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
    [Abstract] [Full Text] [Related]

  • 2. [Therapy of Alzheimer disease].
    Kovács T.
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [Abstract] [Full Text] [Related]

  • 3. Potent beta-amyloid modulators.
    García-Palomero E, Muñoz P, Usan P, Garcia P, Delgado E, De Austria C, Valenzuela R, Rubio L, Medina M, Martínez A.
    Neurodegener Dis; 2008 Mar; 5(3-4):153-6. PubMed ID: 18322376
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing.
    Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Désiré L.
    J Neurochem; 2008 Jul; 106(1):392-404. PubMed ID: 18397369
    [Abstract] [Full Text] [Related]

  • 6. Preclinical evidence of neuroprotection by cholinesterase inhibitors.
    Akaike A.
    Alzheimer Dis Assoc Disord; 2006 Jul; 20(2 Suppl 1):S8-11. PubMed ID: 16772755
    [Abstract] [Full Text] [Related]

  • 7. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS, Rauw G, Baker GB, Kar S.
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY, Tang XC.
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
    Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A.
    Neuropharmacology; 2006 Sep; 51(3):474-86. PubMed ID: 16762377
    [Abstract] [Full Text] [Related]

  • 14. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
    Sugimoto H.
    Chem Biol Interact; 2008 Sep 25; 175(1-3):204-8. PubMed ID: 18577377
    [Abstract] [Full Text] [Related]

  • 15. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M, Kálmán J.
    Neurochem Int; 2008 Nov 25; 53(5):103-11. PubMed ID: 18602955
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Arce MP, Rodríguez-Franco MI, González-Muñoz GC, Pérez C, López B, Villarroya M, López MG, García AG, Conde S.
    J Med Chem; 2009 Nov 26; 52(22):7249-57. PubMed ID: 19856923
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Abeta production by NF-kappaB inhibitors.
    Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M.
    Neurosci Lett; 2007 Mar 19; 415(1):11-6. PubMed ID: 17223266
    [Abstract] [Full Text] [Related]

  • 18. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?
    Mori E, Hashimoto M, Krishnan KR, Doraiswamy PM.
    Alzheimer Dis Assoc Disord; 2006 Mar 19; 20(2 Suppl 1):S19-26. PubMed ID: 16772752
    [Abstract] [Full Text] [Related]

  • 19. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug 19; 21(8):248-9. PubMed ID: 9758554
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.